

Circulation

JOURNAL OF THE AMERICAN HEART ASSOCIATION



Arterial Structure and Function After Recovery From the Metabolic Syndrome. The Cardiovascular Risk in Young Finns Study

Juha Koskinen, Costan G. Magnussen, Leena Taittonen, Leena Räsänen, Vera Mikkilä, Tomi Laitinen, Tapani Rönnemaa, Mika Kähönen, Jorma S.A. Viikari, Olli T. Raitakari and Markus Juonala

Circulation published online Jan 11, 2010;

DOI: 10.1161/CIRCULATIONAHA.109.894584

Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 72514

Copyright © 2010 American Heart Association. All rights reserved. Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://circ.ahajournals.org>

Subscriptions: Information about subscribing to *Circulation* is online at
<http://circ.ahajournals.org/subscriptions/>

Permissions: Permissions & Rights Desk, Lippincott Williams & Wilkins, a division of Wolters Kluwer Health, 351 West Camden Street, Baltimore, MD 21202-2436. Phone: 410-528-4050. Fax: 410-528-8550. E-mail:
journalpermissions@lww.com

Reprints: Information about reprints can be found online at
<http://www.lww.com/reprints>

Arterial Structure and Function After Recovery From the Metabolic Syndrome

The Cardiovascular Risk in Young Finns Study

Juha Koskinen, BM; Costan G. Magnussen, BHM; Leena Taittonen, MD, PhD; Leena Räsänen, PhD; Vera Mikkilä, PhD; Tomi Laitinen, MD, PhD; Tapani Rönnemaa, MD, PhD; Mika Kähönen, MD, PhD; Jorma S.A. Viikari, MD, PhD; Olli T. Raitakari, MD, PhD; Markus Juonala, MD, PhD

Background—The reversibility of ultrasonographic vascular changes associated with the metabolic syndrome (MetS) recovery is unknown. We examined whether spontaneous recovery from MetS (according to the International Diabetes Federation definition) has a favorable effect on vascular properties and evaluated the associations between lifestyle factors and MetS recovery.

Methods and Results—We measured carotid artery intima-media thickness, distensibility, and brachial flow-mediated dilatation by ultrasound in 1673 subjects of the Young Finns Study cohort (age, 31.5 ± 5.0 years in 2001) who participated in follow-up studies in 2001 and 2007. At baseline, no differences in intima-media thickness, carotid artery distensibility, or flow-mediated dilatation were observed between the recovery group (baseline-only MetS) and those with incident (only at follow-up) or persistent (both at baseline and follow-up) MetS. After 6 years, the recovery group had smaller intima-media thickness (mean \pm SEM, 0.62 ± 0.01 versus 0.68 ± 0.01 mm; $P=0.0009$) and higher carotid artery distensibility ($1.98 \pm 0.07\%$ /mm Hg versus $1.56 \pm 0.04\%$ /mm Hg; $P=0.001$) compared with the persistent group and higher flow-mediated dilatation compared with the control group ($9.91 \pm 0.51\%$ versus $8.57 \pm 0.12\%$; $P=0.03$). The recovery group had reduced intima-media thickness progression compared with the persistent group (0.036 ± 0.005 versus 0.079 ± 0.010 mm; $P=0.001$) and reduced carotid artery distensibility change compared with the incident group ($-0.12 \pm 0.05\%$ /mm Hg versus $-0.38 \pm 0.10\%$ /mm Hg; $P=0.03$) over the 6-year follow-up. Differences in carotid artery distensibility levels were attenuated ($P=0.11$) after the inclusion of weight change in the models. MetS recovery was paralleled with significant reductions in waist circumference that independently correlated with increased physical activity and increased attention paid to health habits during the follow-up.

Conclusion—Recovery from the MetS was associated with positive effects on vascular properties during a 6-year follow-up period of young adults. (*Circulation*. 2010;121:392-400.)

Key Words: cardiovascular diseases ■ carotid arteries ■ exercise ■ obesity

The cause of cardiovascular disease is multifaceted.¹ The metabolic syndrome (MetS) is a constellation of several interrelated cardiometabolic risk factors, including obesity, hypertension, dyslipidemia, hyperglycemia, and insulin resistance, often accompanied by hyperinsulinemia.^{2,3} Subjects with MetS are at increased risk of developing type 2 diabetes mellitus and clinical cardiovascular disease.^{4,5}

assessed noninvasively by ultrasound are preclinical markers of vascular health. Increased IMT and impaired Cdist and FMD reflect early atherosclerosis and have been found to predict cardiovascular events.^{6–8} In cross-sectional settings, we⁹ and others¹⁰ have previously shown that young adults with MetS have increased IMT and decreased Cdist. In addition, MetS is associated with accelerated IMT progression.^{11–13} Favorable changes in markers of subclinical atherosclerosis have been shown to occur in response to modifications in cardiovascular risk factors.^{14–19} However, the reversibility of arterial structure and function associated with MetS is unknown.

Clinical Perspective on p 400

Carotid intima-media thickness (IMT), carotid artery distensibility (Cdist), and brachial flow-mediated dilatation (FMD)

Received July 15, 2009; accepted November 17, 2009.

From the Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku (J.K., C.G.M., O.T.R., M.J.), and the Departments of Clinical Physiology (O.T.R.) and Medicine (T.R., J.S.A.V., M.J.), Turku University Hospital and University of Turku, Turku, Finland; Menzies Research Institute, University of Tasmania, Tasmania, Australia (C.G.M.); Department of Pediatrics, Vaasa Central Hospital and University of Oulu, Oulu, Finland (L.T.); Division of Nutrition, University of Helsinki, Helsinki, Finland (L.R., V.M.); Department of Clinical Physiology and Nuclear Medicine, Kuopio University Hospital, Kuopio, Finland (T.L.); and Department of Clinical Physiology, Tampere University Hospital and University of Tampere, Tampere, Finland (M.K.).

Correspondence to Juha Koskinen, Research Center of Applied and Preventive Cardiovascular Medicine, University of Turku, Kiinamyllynkatu 10, FI-20520, Finland. E-mail jkkosk@utu.fi

© 2010 American Heart Association, Inc.

Circulation is available at <http://circ.ahajournals.org>

DOI: 10.1161/CIRCULATIONAHA.109.894584




Figure 1. Study flow diagram. Participants, those lost to follow-up, and reparticipants in blood sampling and physical examination in the cross-sectional study (1980) and follow-up studies (2001, 2007) in the Cardiovascular Risk in Young Finns Study. *Participated at both follow-up studies in 2001 and 2007.

The objective of this study was to address this gap in the literature. First, we determined whether recovery from MetS diagnosis over 6 years has a favorable effect on vascular properties. Second, we examined the associations between lifestyle factors and MetS recovery. We addressed these objectives in a population-based sample of young adults ($n=1673$; mean age at baseline, 31.5 years) participating in the Cardiovascular Risk in Young Finns Study.

Methods

Subjects

The Cardiovascular Risk in Young Finns Study is an ongoing epidemiological study to assess risk factors underlying cardiovascular disease. The first cross-sectional survey was conducted in 1980 when 3596 randomly selected children and adolescents (age range, 3 to 18 years) participated. Thereafter, several follow-up studies have been performed. IMT, Cdist, and FMD were measured in the follow-up studies conducted in 2001 ($n=2265$) and 2007 ($n=2197$). The study flow diagram is shown in Figure 1. The sample for the present analysis (mean age at baseline, 31.5 years in 2001; age range, 24 to 39 years) included those subjects who had undergone ultrasound examinations during both the 2001 and 2007 follow-ups ($n=1809$). The subjects having incomplete metabolic risk factor data from these study years ($n=94$), subjects with type 1 diabetes mellitus ($n=12$), and those female participants who were pregnant at either time point ($n=30$) were excluded. A total of 1673 men and women were included in the present analysis. Subjects gave written informed consent, and the study was approved by local ethics committees.

Clinical Characteristics

Height, weight, and waist circumferences were measured. Body mass index was calculated as weight in kilograms divided by height in meters squared. Blood pressure was measured with a random-zero

sphygmomanometer. The average of 3 measurements was used in the analysis.

Venous blood samples were collected after a 12-hour fast. Lipid determinations for triglycerides, total cholesterol, and high-density lipoprotein (HDL) cholesterol were done with standard methods.²⁰ Low-density lipoprotein (LDL) cholesterol was calculated with the Friedewald formula²¹ for subjects with triglycerides <4 mmol/L. Glucose concentrations were analyzed enzymatically, and serum insulin was measured by microparticle enzyme immunoassay kit. High-sensitivity serum C-reactive protein (CRP) was analyzed by an automated analyzer with a latex turbidimetric immunoassay kit. Details of methods have been described previously.²⁰

Smoking habits, physical activity, and attention paid to health habits were ascertained with questionnaires.²⁰ Physical activity is represented as a metabolic equivalent index by assessing the duration, intensity, and frequency of physical activity, including leisure-time physical activity and commuting.²² As part of the questionnaire, participants were asked to indicate the degree to which they paid attention to healthy lifestyle habits: (1) not at all, (2) quite a lot, (3) quite little, or (4) considerable. Information on food consumption was assessed with food frequency questionnaires. In 2001, a short nonquantitative food frequency questionnaire with 20 items (representing the main food groups) was used to estimate the number of weekly portions of selected food groups. In the latest follow-up in 2007, the participants completed a more comprehensive, semi-quantitative 128-item food frequency questionnaire that provided an estimate of food consumption in grams per day. Detailed information on the food frequency questionnaires and their validity has been published elsewhere.^{23,24}

Ultrasound Imaging

An ultrasound imaging device with a high-resolution system (Sequoia 512, Acuson, Calif) was used. Ultrasound studies were performed by trained sonographers following a standardized protocol. Measurements were made offline from stored digital images. All ultrasound scans were analyzed by 1 reader (same reader in 2001 and

2007) blinded to the subjects' details. The methods have been described in detail previously.^{25–27} To assess intraindividual reproducibility of ultrasound measurements, we reexamined 57 subjects 3 months after the initial visit in 2001 (2.5% random sample). The 3-month between-visit coefficients of variations were 6.4% for IMT, 14.3% for Cdist, and 26.0% for FMD measures in 2001. Mean IMT was derived from a minimum of 4 IMT measurements from the posterior (far) wall of the left carotid artery \approx 10 mm proximal to the carotid bifurcation.

To assess Cdist, the best-quality cardiac cycle was selected from a continuous 5-second image file. The common carotid diameter was measured at least twice during end diastole. Ultrasound and concomitant brachial blood pressure measurements were used to calculate Cdist: $Cdist = [(D_s - D_d)/D_d]/(P_s - P_d)$, where D_d is diastolic diameter, D_s is systolic diameter, P_s is systolic blood pressure, and P_d is diastolic blood pressure.²⁶

To assess brachial FMD, the left brachial artery diameter was measured at rest and during reactive hyperemia. Increased flow was induced by inflation of a pneumatic tourniquet placed around the forearm to a pressure of 250 mm Hg for 4.5 minutes followed by release. The average of 3 measurements at rest and 40, 60, and 80 seconds after cuff release was used to derive maximum FMD. The maximal vessel diameter in scans after reactive hyperemia was expressed as the percentage relative to resting scan (100%).

Definition of the MetS

Subjects were considered to have MetS when the diagnostic criterion of International Diabetes Federation definition of MetS was fulfilled. MetS was diagnosed as waist circumference \geq 94 cm for men and \geq 80 cm for women plus any 2 of the following 4 factors: raised triglycerides (>1.695 mmol/L [150 mg/dL]) or specific treatment for this lipid abnormality, reduced HDL cholesterol (<1.036 mmol/L [40 mg/dL] in men, <1.295 mmol/L [50 mg/dL] in women) or specific treatment for this lipid abnormality, raised blood pressure (blood pressure \geq 130/85 mm Hg) or treatment of previously diagnosed hypertension, or raised fasting plasma glucose (5.6 mmol/L [101 mg/dL]) or previously diagnosed type 2 diabetes mellitus.²⁸ Subjects were classified further into 4 groups according to their MetS status at the 2 time points: recovery group (MetS at baseline but not at follow-up; $n=71$), incident group (MetS at follow-up but not at baseline; $n=194$), persistent group (MetS both at baseline and at follow-up; $n=166$), and control group (no MetS at baseline or at follow-up by any MetS definition; $n=1242$).

Statistical Methods

To examine whether selection bias was present, we created a dichotomous (yes/no) variable for participation in 2001 and 2007 (yes) or 2001 only (no) and used this as the outcome variable in a logistic regression model that included age, sex, and baseline MetS. Characteristics of study subjects in 2001 and 2007 and changes in risk factors and lifestyle factors between 2001 and 2007 were summarized for each study group (control, recovery, incident, and persistent), and linear regression models adjusted for age and sex were used to test for significant trends. Pairwise comparisons between study groups were performed with logistic regression model adjusted for age and sex. To study the associations between change in metabolic risk factors and change in lifestyle variables, we first calculated age- and sex-specific z -score values (standardized values) at baseline and follow-up for metabolic risk components (waist circumference, systolic blood pressure, triglycerides, HDL cholesterol, and glucose) and lifestyle variables (physical activity, attention paid to health habits, and alcohol, vegetable, fruit, meat, and fish consumption). Second, we generated a change variable by subtracting the baseline value from the follow-up value. We then examined a series of multiple regression models. The models included age- and sex-specific z -score values for change in physical activity, attention paid to health habits, and alcohol, vegetable, fruit, meat, and fish consumption as dependent variables and individual change in metabolic risk component as the outcome variable. The normality assumptions of the residuals were assessed by examining histograms of the residuals and normal probability plots. Values for plasma

triglycerides, insulin, CRP, metabolic equivalent index, and dietary habits were \log_e transformed to correct for skewness. Thirty-nine and 116 subjects used antihypertensive medication in 2001 and 2007, respectively. Seven and 34 subjects were on lipid-lowering medication in 2001 and 2007. The results were essentially similar when subjects with medications were excluded from analyses. Statistical analyses were performed with SAS version 9.1 (SAS Institute, Inc, Cary, NC), and statistical significance was inferred at a 2-tailed value of $P<0.05$.

Associations Between MetS Status and Ultrasound Outcome Variables (IMT, Cdist, and FMD)

ANCOVA (age and sex as covariates) followed by the Tukey multiple-comparison posthoc test was used to compare mean IMT, Cdist, and FMD between the study groups. To assess whether weight change or MetS component changes have accounted for the differences in vascular parameters between study groups, we adjusted the models for 6-year change in weight, waist circumference, systolic blood pressure, triglycerides, HDL cholesterol, and glucose. For these analyses, variables were introduced into the model first 1 at a time and then simultaneously as covariates. We found an inverse correlation between baseline IMT and 6-year IMT progression ($r=-0.39$), between Cdist and Cdist regression ($r=-0.57$), and between FMD and FMD progression ($r=-0.60$). Therefore, all analyses studying change in ultrasound variables were also adjusted for their respective baseline (2001) measures. Linear regression was used to examine for significant MetS group-by-sex interactions for each vascular measure (IMT, Cdist, and FMD). Because no significant interactions were observed, we did not stratify our analyses by sex.

The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.

Results

Characteristics of Study Subjects

The number of participants, reparticipants, and those lost-to follow-up in 1980, 2001, and 2007 are shown in Figure 1. Among those lost to follow-up in 2001 or 2007 ($n=1768$), there were more men than women (55% versus 45%; $P<0.0001$). No difference was observed in baseline MetS prevalence (in 2001) between subjects who were lost to follow-up between 2001 and 2007 (17.3%) compared with participants (14.5%; $P=0.14$).

The baseline (2001) and follow-up (2007) data of study subjects according to MetS groups are shown in Table 1. Significant linear trends from the control group to the persistent group were observed for waist circumference, body mass index (BMI), weight, blood pressure, total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, glucose, insulin, CRP, and metabolic equality index at follow-up.

Six-Year Risk Factor Changes

Table 2 shows the age- and sex-adjusted changes in risk factors and lifestyle habits between 2001 and 2007. A linear increasing trend from the control group to the persistent group was observed for change in waist circumference, BMI, weight, triglycerides, glucose, and insulin, and a decreasing trend for change in HDL cholesterol was seen. The most favorable changes were observed in the recovery group during the 6-year follow-up period. Despite nonsignificant trends, we observed a difference in systolic blood pressure and CRP between the recovery and incident groups ($P<0.0001$ and $P<0.0001$, respectively) and between the

Table 1. Characteristics of Study Subjects

	Year	Control Group	Recovery Group	Incident Group	Persistent Group	<i>P</i> for Trend
Subjects, n		1242	71	194	166	0.40
Age, y	2001	32.7±4.9	32.8±4.7	33.4±4.6	31.5±5.0	<0.0001
Male sex, %		47	55	63	41	<0.0001
Waist circumference, cm	2001	80±10	95±10	89±10	102±10	<0.0001
	2007	84±11	95±12	99±10	106±11	<0.0001
BMI, kg/m ²	2001	23.6±3.4	29.2±4.3	26.5±3.6	31.2±4.4	<0.0001
	2007	24.5±3.7	28.5±4.4	28.9±3.8	32.2±4.9	<0.0001
Weight, kg	2001	70.1±12.9	86.1±16.1	79.8±12.9	94.8±16.3	<0.0001
	2007	72.7±13.7	83.5±14.8	87.2±14.9	97.8±18.3	<0.0001
Systolic blood pressure, mm Hg	2001	114±12	121±13	121±13	128±14	<0.0001
	2007	118±13	120±11	128±14	131±16	<0.0001
Diastolic blood pressure, mm Hg	2001	69±9	76±10	75±10	80±12	<0.0001
	2007	74±10	77±10	82±10	85±12	<0.0001
Total cholesterol, mmol/L	2001	5.00±0.89	5.44±0.96	5.39±1.01	5.64±1.05	<0.0001
	2007	4.94±0.84	5.10±0.89	5.36±0.94	5.43±0.97	<0.0001
LDL cholesterol, mmol/L	2001	3.18±0.80	3.49±0.86	3.52±0.89	3.64±0.95	<0.0001
	2007	3.03±0.75	3.21±0.79	3.33±0.86	3.39±0.85	<0.0001
HDL cholesterol, mmol/L	2001	1.34±0.30	1.10±0.23	1.23±0.29	1.00±0.24	<0.0001
	2007	1.41±0.32	1.27±0.27	1.15±0.27	1.07±0.28	<0.0001
Triglycerides,* mmol/L	2001	1.00 (0.80–1.30)	1.76 (1.60–2.10)	1.28 (1.00–1.70)	2.09 (1.70–2.70)	<0.0001
	2007	1.02 (0.75–1.36)	1.24 (0.95–1.46)	1.77 (1.36–2.38)	2.05 (1.56–2.78)	<0.0001
Glucose, mmol/L	2001	4.93±0.40	5.14±0.44	5.14±0.37	5.42±0.91	<0.0001
	2007	5.16±0.45	5.23±0.41	5.66±0.69	5.85±1.13	<0.0001
Insulin,* IU/L	2001	5.6 (4.0–8.0)	9.5 (7.0–13.0)	7.3 (5.0–10.0)	12.6 (9.0–18.0)	<0.0001
	2007	5.7 (3.8–8.5)	7.8 (5.2–12.1)	11.36 (8.1–16.4)	14.7 (9.9–20.1)	<0.0001
CRP,* mmol/L	2001	0.65 (0.27–1.34)	1.91 (0.86–3.76)	0.89 (0.36–1.88)	1.75 (0.91–3.05)	<0.0001
	2007	0.74 (0.34–1.46)	1.18 (0.54–2.38)	1.36 (0.67–2.51)	1.84 (0.95–3.52)	<0.0001
Metabolic equality index, kcal · kg ⁻¹ · h ⁻¹	2001	11.0 (5.0–32.5)	10.0 (2.0–28.4)	7.7 (1.9–29.5)	5.6 (0.7–18.9)	<0.0001
	2007	11.3 (5.0–32.6)	10.8 (3.0–31.3)	7.20 (1.1–19.6)	6.0 (0.7–19.5)	<0.0001
Vegetable consumption,* frequency/wk	2001	5.8 (3.0–9.5)	5.3 (3–9.5)	5.4 (3.0–6.3)	5.0 (3.0–6.3)	0.02
g/d	2007	224 (157–330)	205 (136–352)	212 (151–325)	213 (157–331)	0.63
Fruit consumption,* frequency/wk	2001	5.9 (3.0–9.5)	5.6 (3.0–9.5)	5.3 (3.0–9.5)	5.0 (3.0–6.3)	0.03
g/d	2007	182 (84–284)	174 (77–275)	154 (60–259)	158 (67–238)	0.26
Meat consumption,* frequency/wk	2001	3.3 (1.3–6.3)	3.5 (3.0–6.3)	3.6 (3.0–6.3)	3.5 (3.0–6.3)	0.20
g/d	2007	136 (92–187)	154 (104–214)	145 (105–188)	180 (111–234)	0.0005
Fish consumption,* frequency/wk	2001	1.1 (0.3–1.3)	1.0 (0.3–1.3)	1.0 (0.3–1.3)	1.0 (0.3–1.3)	0.11
g/d	2007	33 (21–48)	34 (23–53)	35 (20–52)	36 (18–54)	0.99

Values are mean±SD or geometric mean (25th–75th percentiles) as appropriate. *P* values are from linear regression models adjusted for age and sex.

*Geometric mean values.

recovery and persistent groups ($P=0.02$ and $P=0.002$, respectively).

Next, age- and sex-specific standardized changes in multiple lifestyle variables (physical activity, attention paid to health habits, and alcohol, vegetable, fruit, meat, and fish consumption) were regressed against change in metabolic components. In these models, all lifestyle variables were included simultaneously in the models as covariates. De-

crease in physical activity and decrease in attention paid to health habits were independently associated with increase in waist circumference ($\beta=-0.05\pm0.02$, $P=0.005$; and $\beta=-0.08\pm0.02$, $P<0.0001$, respectively). A decrease in attention paid to health habits was independently associated with an increase in systolic blood pressure ($\beta=-0.06\pm0.02$; $P=0.03$), and an increase in physical activity was associated with an increase in HDL cholesterol ($\beta=0.06\pm0.03$; $P=0.03$).

Table 2. Changes in Risk Factors and Lifestyle Habits Between 2001 and 2007 According to MetS Group

Change Between 2001–2007	Control Group	Recovery Group	Incident Group	Persistent Group	<i>P</i> for Trend
ΔWaist, cm	4.2±6.0	0.8±8.4	9.3±7.0	4.4±6.5	<0.0001
ΔBMI, kg/m ²	0.9±1.9	-0.7±3.3	2.5±2.3	1.0±2.4	<0.0001
ΔWeight, kg	2.6±5.5	-2.6±10.1	7.5±7.2	3.1±7.2	<0.0001
ΔSystolic blood pressure, mm Hg	4.0±9.9	-1.5±12.6	7.6±11.0	3.5±13.4	0.46
ΔDiastolic blood pressure, mm Hg	5.2±8.6	0.6±9.6	7.6±9.5	4.3±10.1	0.87
ΔTotal cholesterol, mmol/L	-0.07±0.67	-0.34±0.74	-0.03±0.88	-0.21±0.91	0.09
ΔLDL, mmol/L	-0.15±0.58	-0.27±0.69	-0.17±0.75	-0.26±0.88	0.10
ΔHDL, mmol/L	0.07±0.23	0.17±0.22	-0.08±0.20	0.07±0.18	<0.0001
ΔTriglycerides, mmol/L	0.02±0.38	-0.34±0.36	0.32±0.47	-0.01±0.43	0.004
ΔGlucose, mmol/L	0.23±0.43	0.09±0.39	0.51±0.67	0.42±0.83	<0.0001
ΔInsulin, IU/L	-0.005±0.61	-0.19±0.62	0.44±0.51	0.17±0.52	<0.0001
ΔCRP, mmol/L	0.13±1.10	-0.47±1.16	0.43±1.06	0.05±0.97	0.70
ΔMetabolic equality index, kcal·kg ⁻¹ ·h ⁻¹	0.04±2.33	0.20±2.40	-0.40±2.40	-0.03±2.0	0.28
ΔAlcohol consumption, drinks/d	0.01±0.47	0.13±0.54	0.01±0.47	0.02±0.45	0.56
ΔSmokers, %	-5	-8	-2	-5	0.73
ΔAttention paid to health habits, points	-0.10±0.02	-0.34±0.11	0.04±0.07	-0.24±0.07	0.71

Values are mean±SD. *P* values are from linear regression models adjusted for age and sex.

Associations Between MetS Status and Vascular Measures

Figure 2 shows the age- and sex-adjusted mean values of IMT, Cdist, and FMD between study groups in 2001 and 2007. At baseline, in 2001, subjects in the recovery group had lower Cdist compared with the control group. At the follow-up in 2007, subjects in the recovery group had smaller IMT (Figure 2A) and higher Cdist (Figure 2B) compared with subjects with persistent MetS. The difference in Cdist at baseline between the recovery and control groups was diminished at the follow-up in 2007. In addition, those in the recovery group had higher FMD compared with subjects in the control group at the follow-up in 2007 (Figure 2C).

Next, we assessed whether weight change or MetS component changes have accounted for the findings. These analyses were performed as follows. First, we included changes in weight, waist circumference, systolic blood pressure, triglycerides, HDL cholesterol, and glucose one at a time in the models to assess the effect of individual risk components. Second, we included all variables simultaneously as covariates. Results for IMT and FMD in 2007 remained similar after we included covariates individually or simultaneously in the model. The difference in Cdist between the recovery group and the persistent group at follow-up in 2007 was attenuated when 6-year weight change was included as a covariate (*P*=0.11).

Figure 3 shows the age- and sex-adjusted mean values for the 6-year change in IMT, Cdist, and FMD according to MetS status. Subjects in the recovery group had a decreased rate of IMT progression compared with the persistent group (Figure 3A) and a decreased rate of Cdist regression compared with the incident group (Figure 3B). No differences were observed for change in FMD between study groups (Figure 3C).

The results were similar for IMT and FMD progression after adjustment separately or simultaneously for 6-year change in weight, waist circumference, systolic blood pres-

sure, triglycerides, HDL cholesterol, and glucose. Similar results were also obtained after adjustment for baseline IMT or baseline FMD. The difference in Cdist regression between the recovery group and the persistent group was attenuated (*P*=0.90) when weight change was included in the model as a covariate. Of the individual MetS component changes, inclusion of the 6-year change in waist circumference and triglycerides also diluted the difference between the recovery group and the persistent group (*P* for Cdist regression=0.54 and 0.20, respectively). The results remained similar after inclusion of baseline Cdist in the model.

Discussion

In the present study, we observed that recovery from the MetS over a 6-year period had a positive effect on vascular properties. Subjects in the MetS recovery group had smaller IMT and higher Cdist after the follow-up compared with subjects with persistent MetS, although at baseline there were no differences. In addition, those in the recovery group had a decreased rate of IMT progression compared with subjects who had persistent MetS and a decreased rate of Cdist regression compared with subjects with incident MetS over the 6-year period. Differences in Cdist levels and regression between study groups were attenuated when weight change was taken into account.

To the best of our knowledge, this is the first study to demonstrate the reversibility of subclinical atherosclerotic markers associated with recovery from MetS diagnosis. Our findings are in line with earlier reports demonstrating the effects of MetS exposure on the vasculature. We¹³ and others^{11,12} have shown that MetS is associated with accelerated IMT progression. In addition, all current MetS definitions identify individuals with evidence of increased IMT and decreased Cdist.²⁷ It has been established that preclinical atherosclerosis is not an irreversible but rather a dynamic process. Different interventions on cardiovascular risk factors




Figure 2. Ultrasound data (mean and 95% confidence intervals) at the 2001 and 2007 follow-ups using ANCOVA (age and sex as covariates) followed by the Tukey multiple-comparison posthoc test.



(dyslipidemia, hypertension, diabetes mellitus, and obesity) have been shown to slow or even regress the progression of atherosclerosis.^{14–19} Pathological data from deceased subjects have shown that in young adults (age, 30 to 39 years)

preclinical atherosclerotic lesions in the common carotid artery were dominated by foam cell formations.²⁹ The internalization of LDL particles (which may be enzymatically and oxidatively modified) by macrophages results in the forma-




Figure 3. Comparison of age- and sex-adjusted values (mean and 95% confidence intervals) of (A) IMT progression, (B) Cdist regression, and (C) FMD progression between study subjects (recovery vs control, recovery vs incident, and recovery vs persistent). Comparisons were performed with ANCOVA followed by the Tukey multiple-comparison posthoc test.

tion of foam cells, which are known to predispose to fatty-streak formation in atherosclerosis.^{29,30} Foam cell formation is an early manifestation of atherosclerosis, and modified LDL particles may still be subsequently cleared from the artery wall to the liver by HDL cholesterol.³¹ Furthermore, we have previously shown that 6-year change in HDL cholesterol was inversely associated with IMT progression.¹³ The reversibility of foam cell lesions may explain the dynamic ultrasonographic changes in common carotid artery in subjects with MetS observed in this study. On the basis of these data, favorable changes in vasculature can be achieved by improving metabolic risk factors.

The difference in Cdist change between the recovery group and the incident group was diluted after adjustment for weight or waist circumference changes, suggesting that favorable changes in Cdist may have been mediated by weight loss. In addition, subjects who were recovered from MetS diagnosis had reduced their adiposity levels compared with the other study groups. We also observed that a decrease in physical activity and attention paid to health habits were independently associated with an increase in waist circumference. Furthermore, paying less attention to health habits was independently associated with an increase in systolic blood pressure and an increase in physical activity associated with an increase in HDL cholesterol. Previous studies conducted in samples of overweight adults suggest that weight loss induced by nutritional and exercise intervention is associated with correction of arterial structure and function.^{18,19} As reported in other studies,^{18,32,33} the weight change observed in the recovery group was associated with favorable changes in blood

pressure, lipids, glucose, and insulin. All these metabolic changes have been validated as determinants of vascular structure and function across all age groups.^{10,11,26,27,33} In addition, insulin has been hypothesized as the main mechanism responsible for changes in sympathetic stimulation,³⁴ which is accompanied by a reduction in Cdist.³⁵

In the present study, we unexpectedly observed that in the control and persistent groups, FMD values increased over the 6-year period. We have previously shown in this cohort a curvilinear association between BMI and FMD, so that these variables are directly associated in subjects with BMI values less than ≈ 33 kg/m².²⁷ This prior finding provides a possible explanation for the present observation because subjects in the control and persistent groups had increased BMI levels during the 6-year follow-up.

Our study has limitations. In our laboratory, the reproducibility of IMT measurements is fairly good (coefficient of variation, 6.4%), whereas the coefficient of variation values for Cdist and FMD are higher (14.3% and 26.0%, respectively). Therefore, because of the large within-subject variability of especially FMD,²⁷ the nonsignificant differences in FMD and FMD change between the recovery group and the persistent and incident groups should be interpreted cautiously. Another potential limitation of our study was selection bias resulting from loss to follow-up. However, we observed no difference in MetS prevalence at baseline among subjects who were lost to follow-up between 2001 and 2007 compared with participants at both time points. When comparing baseline risk factors in the recovery and persistent MetS groups, we observed that subjects in the recovery group

had more favorable levels of metabolic variables. It is therefore possible that those with less severe MetS may be more likely to recover. However, at baseline, no differences in vascular parameters were observed between the MetS study groups. Because our study cohort was racially homogeneous, the generalizability of our results is limited to white European subjects. In addition, we are not currently able to study these associations with clinical outcome of cardiovascular events. Instead, we have used vascular ultrasound measures as indicators of the atherogenic process. Strengths of this study include the large, randomly selected cohort of young men and women free of clinical cardiovascular disease.

A better understanding of the underlying mechanisms and the development of lifestyles involved in the dynamics of atherosclerosis are needed for developing early interventions to reduce the incidence of later cardiovascular disease in young adults. Adverse developments of lifestyles in childhood and young adulthood are known to have a strong influence on all the components of MetS and thus on the progression of atherosclerosis. The present study suggests that arterial structure and function may be restored in young adults with MetS by improving metabolic risk factors and weight reduction.

Sources of Funding

This study was supported financially by the Academy of Finland (grants 117797, 126925, and 121584); the Social Insurance Institution of Finland; government grants to the Tampere, Kuopio, and Turku University Hospitals; the Finnish Foundation of Cardiovascular Research; the Turku University Foundation; Turku University; the Juho Vainio Foundation; the Lydia Maria Julin Foundation; the Finnish Medical Foundation; and the Research Foundation of Orion Corp.

Disclosures

None.

References

- Badimon JJ, Fuster V, Chesebro JH, Badimon L. Coronary atherosclerosis: a multifactorial disease. *Circulation*. 1993;87(suppl):II-3-II-16.
- Reaven GM. Banting Lecture 1988: role of insulin resistance in human disease. *Diabetes*. 1988;37:1595-1607.
- Balkau B, Charles MA. Comment on the provisional report from the WHO consultation: European Group for the Study of Insulin Resistance (EGIR). *Diabet Med*. 1999;16:442-443.
- Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. *JAMA*. 2002;288:2709-2716.
- Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, Montori VM. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. *J Am Coll Cardiol*. 2007;49:403-414.
- Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. *Circulation*. 2007;115:459-467.
- Yeboah J, Crouse JR, Hsu FC, Burke GL, Herrington DM. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. *Circulation*. 2007;115:2390-2397.
- Leone N, Ducimetiere P, Garipey J, Courbon D, Tzourio C, Dartigues JF, Ritchie K, Alperovitch A, Amouyel P, Safar ME, Zureik M. Distension of the carotid artery and risk of coronary events: the three-city study. *Arterioscler Thromb Vasc Biol*. 2008;28:1392-1397.
- Mattsson N, Rönnemaa T, Juonala M, Viikari JS, Jokinen E, Hutri-Kähönen N, Kähönen M, Laitinen T, Raitakari OT. Arterial structure and function in young adults with the metabolic syndrome: the Cardiovascular Risk in Young Finns Study. *Eur Heart J*. 2008;29:784-791.
- Tzou WS, Douglas PS, Srinivasan SR, Bond MG, Tang R, Chen W, Berenson GS, Stein JH. Increased subclinical atherosclerosis in young adults with metabolic syndrome: the Bogalusa Heart Study. *J Am Coll Cardiol*. 2005;46:457-463.
- Hassinen M, Komulainen P, Lakka TA, Väisänen SB, Haapala I, Gylling H, Alen M, Schmidt-Trucksäss A, Nissinen A, Rauramaa R. Metabolic syndrome and the progression of carotid intima-media thickness in elderly women. *Arch Intern Med*. 2006;166:444-449.
- Zanchetti A, Hennig M, Baurecht H, Tang R, Cuspidi C, Carugo S, Mancia G. Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness. *J Hypertens*. 2007;25:2463-2470.
- Koskinen J, Kähönen M, Viikari JS, Taittonen L, Laitinen T, Rönnemaa T, Lehtimäki T, Hutri-Kähönen N, Pietikäinen M, Jokinen E, Helenius H, Mattsson N, Raitakari OT, Juonala M. Conventional cardiovascular risk factors and metabolic syndrome in predicting carotid intima-media thickness progression in young adults: the Cardiovascular Risk in Young Finns Study. *Circulation*. 2009;120:229-236.
- Salonen R, Nyssönen K, Porkkala E, Rummukainen J, Belder R, Park JS, Salonen JT. Kuopio Atherosclerosis Prevention Study (KAPS): a population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. *Circulation*. 1995;92:1758-1764.
- Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM, for the ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. *JAMA*. 2006;295:1556-1565.
- Girerd X, Giannattasio C, Moulin C, Safar M, Mancia G, Laurent S. Regression of radial artery wall hypertrophy and improvement of carotid artery compliance after long-term antihypertensive treatment in elderly patients. *J Am Coll Cardiol*. 1998;31:1064-1073.
- Nathan DM, Lachin J, Cleary P, Orchard T, Brillon DJ, Backlund JY, O'Leary DH, Genuth S, for the Diabetes Control and Complications Trial; Epidemiology of Diabetes Interventions and Complications Research Group. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. *N Engl J Med*. 2003;348:2294-2303.
- Raitakari M, Ilvonen T, Ahotupa M, Lehtimäki T, Harmoinen A, Suominen P, Elo J, Hartiala J, Raitakari OT. Weight reduction with very-low-caloric diet and endothelial function in overweight adults: role of plasma glucose. *Arterioscler Thromb Vasc Biol*. 2004;24:124-128.
- Meyer AA, Kundt G, Lenschow U, Schuff-Werner P, Kienast W. Improvement of early vascular changes and cardiovascular risk factors in obese children after a six-month exercise program. *J Am Coll Cardiol*. 2006;48:1865-1870.
- Juonala M, Viikari JS, Hutri-Kähönen N, Pietikäinen M, Jokinen E, Taittonen L, Marniemi J, Rönnemaa T, Raitakari OT. The 21-year follow-up of the Cardiovascular Risk in Young Finns Study: risk factor levels, secular trends and east-west difference. *J Intern Med*. 2004;255:457-468.
- Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem*. 1972;18:499-502.
- Telama R, Yang X, Viikari J, Välimäki I, Wanne O, Raitakari O. Physical activity from childhood to adulthood: a 21-year tracking study. *Am J Prev Med*. 2005;28:267-273.
- Mikkilä V, Räsänen L, Raitakari OT, Pietinen P, Viikari J. Consistent dietary patterns identified from childhood to adulthood: the Cardiovascular Risk in Young Finns Study. *Br J Nutr*. 2005;93:923-931.
- Paalanen L, Männistö S, Virtanen MJ, Knekt P, Räsänen L, Montonen J, Pietinen P. Validity of a food frequency questionnaire varied by age and body mass index. *J Clin Epidemiol*. 2006;59:994-1001.
- Raitakari OT, Juonala M, Kähönen M, Taittonen L, Laitinen T, Mäki-Torkko N, Jarvisalo MJ, Uhari M, Jokinen E, Rönnemaa T, Åkerblom HK, Viikari JS. Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. *JAMA*. 2003;290:2277-2283.
- Juonala M, Jarvisalo MJ, Mäki-Torkko N, Kähönen M, Viikari JS, Raitakari OT. Risk factors identified in childhood and decreased carotid

- artery elasticity in adulthood: the Cardiovascular Risk in Young Finns Study. *Circulation*. 2005;112:1486–1493.
27. Juonala M, Viikari JS, Laitinen T, Marniemi J, Helenius H, Rönkä T, Raitakari OT. Interrelations between brachial endothelial function and carotid intima-media thickness in young adults: the Cardiovascular Risk in Young Finns Study. *Circulation*. 2004;110:2918–2923.
 28. Alberti KG, Zimmet P, Shaw J, for the IDF Epidemiology Task Force Consensus Group. The metabolic syndrome: a new worldwide definition. *Lancet*. 2005;366:1059–1062.
 29. Dalager S, Paaske WP, Kristensen IB, Laurberg JM, Falk E. Artery-related differences in atherosclerosis expression: implications for atherogenesis and dynamics in intima-media thickness. *Stroke*. 2007;38:2698–2705.
 30. Ross R. Atherosclerosis: an inflammatory disease. *N Engl J Med*. 1999;340:115–126.
 31. Assmann G, Gotto AM Jr. HDL cholesterol and protective factors in atherosclerosis. *Circulation*. 2004;109(suppl):III-8–III-14.
 32. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. *Am J Clin Nutr*. 1992;56:320–328.
 33. Dengel DR, Kelly AS, Olson TP, Kaiser DR, Dengel JL, Bank AJ. Effects of weight loss on insulin sensitivity and arterial stiffness in overweight adults. *Metabolism*. 2006;55:907–911.
 34. Vollenweider P, Randin D, Tappy L, Jequier E, Nicod P, Scherrer U. Impaired insulin-induced sympathetic neural activation and vasodilation in skeletal muscle in obese humans. *J Clin Invest*. 1994;93:2365–2371.
 35. Mangoni AA, Mircoli L, Giannattasio C, Mancia G, Ferrari AU. Effect of sympathectomy on mechanical properties of common carotid and femoral arteries. *Hypertension*. 1997;30:1085–1088.

CLINICAL PERSPECTIVE

Increased carotid intima-media thickness and impaired carotid artery distensibility and brachial flow-mediated dilatation reflect early atherosclerosis and have been found to predict cardiovascular events. Preclinical atherosclerosis is a reversible, dynamic process. Different interventions on cardiovascular risk factors (dyslipidemia, hypertension, diabetes mellitus, and obesity) have been shown to slow or even regress atherosclerosis. However, the reversibility of ultrasonographic preclinical vascular changes associated with metabolic syndrome recovery is unknown. Our results from a population-based study of young adults (n=1673; age, 24 to 39 years at baseline) suggest that arterial structure and function are restored after spontaneous recovery from the metabolic syndrome. Furthermore, recovery from the metabolic syndrome was associated with weight loss, increased physical activity, and favorable changes in blood pressure, lipids, glucose, and insulin. Therefore, major efforts are needed for the reduction of overweight and an increase in physical activity, particularly in young adults with the metabolic syndrome to reduce the risk of cardiovascular disease later in their life.



Circulation
 JOURNAL OF THE AMERICAN HEART ASSOCIATION